New human trials for novel antibody offer hope for immediate protection against deadly Nipah 3 July 2024; OSLO; CALIFORNIA; Twenty-five years after the first human outbreak of Nipah virus, a novel Nipah monoclonal antibody—which could offer people at risk of...
BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease As a part of ongoing national preparedness efforts against filoviruses, BARDA continues to support Mapp’s monoclonal antibody therapeutic,...
BARDA collaborates with Mapp Biopharmaceutical, Inc. to advance the development of a therapeutic for Marburg virus disease To further enhance preparedness against health security threats, BARDA is extending a partnership with Mapp...
ASPR awards $110 million to advance development, procure therapeutic for Sudan ebolavirus The Administration for Strategic Preparedness and Response (ASPR) today announced a $109.8 million contract with Mapp Biopharmaceutical Inc., for the advanced...
BARDA partners with Mapp Biopharmaceutical, Inc. to develop next generation therapeutic for Botulinum Neurotoxin BARDA and its partner Mapp Biopharmaceutical Inc. will explore the potential of a new monoclonal antibody (mAb) based therapeutic for Botulinum Neurotoxin...
MappBio Announces Contract with BARDA for MBP091 as a pan-Marburg Medical Countermeasure June 11, 2019 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded an advanced research and...
Public Release
MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure September 28, 2018 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded a contract (HHSO100201800024C) of $14.8 million with options for...